Latest Breaking News On - Ketabon program - Page 1 : comparemela.com

Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At American Society Of Clinical Psychopharmacology Annual Meeting

Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At American Society Of Clinical Psychopharmacology Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

South africaSwitzerland generalMiami beachBaden wübergUnited statesDevelco pharmaHans erikssonKetabon gmbhAnne donohoeAmerican society of clinical psychopharmacologyKetabon programBrain healthDepression at american societyHolding gmbClinical psychopharmacologyAnnual meeting

Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO®, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral Treatment, at doses used for Treatment-Resistant Depression

Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO®, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral Treatment, at doses used for Treatment-Resistant Depression
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Baden wübergCzech republicUnited statesSouth africaSwitzerland generalHans erikssonMckenna millerSophia bashfordDevelco pharmaKetabon gmbhHome administrationBrain healthKetabon programHolding gmbProlonged release oral ketamine formulationFinds less incidence

Ketabon GmbH Reports Top-Line Results from Phase 2 Trial of Take-at-Home, Oral Ketamine Option for Treatment-Resistant Depression

Ketabon GmbH Reports Top-Line Results from Phase 2 Trial of Take-at-Home, Oral Ketamine Option for Treatment-Resistant Depression
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Czech republicSwitzerland generalBaden wübergSouth africaAnne donohoeSophia bashfordHans erikssonMartin walterDevelco pharmaHolding gmbBrain healthKetabon programUniversity jenaHead of the department psychiatryGmbh reports top line resultsOral ketamine option

Investegate |HMNC Holding GmbH Announcements | HMNC Holding GmbH: HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression

Investegate announcements from HMNC Holding GmbH, HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression

Baden wübergSwitzerland generalSouth africaAnne donohoeSophia bashfordHans erikssonDevelco pharmaKetabon programBrain healthHolding gmbHmnc brain healthOral prolonged release ketamineTopline results expectedTreatment resistant depressionChief medical officerDepression rating scale

HMNC Holding GmbH: HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression

KET01 Phase 2 Clinical Trial with Topline Results Expected Mid-YearMUNICH, Germany, March 28, 2023 (GLOBE NEWSWIRE) HMNC Brain Health ("HMNC' or the "Company"), a global clinical stage biopharmaceutical

Switzerland generalBaden wübergSouth africaDevelco pharmaHans erikssonBrain healthKetabon programHolding gmbTopline results expectedTreatment resistant depressionChief medical officerDepression rating scaleMajor depressive disorderMiddle east